Third, the cross-sectional design of the study limited ability to evaluate whether PhA or other markers such as NT-proBNP, measured at a single time point or tracked over time could offer insights into the clinical outcomes and prognosis of patients with HF. The gene discussed is NPPB; the disease is hydrops fetalis.